pharma · Respiratory Syncytial Virus Infections · Asthma
MedImmune
MedImmune clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Gaithersburg, USA
- Founded
- 1987
- Employees
- 896
- Programs
- 9
- Drugs
- 7
- Patents
- 0
MedImmune projects
9 ClinicalTrials.gov programs sponsored by MedImmune.
MedImmune has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CAIV-T
MedImmune
Influenza
1 trial -
Durvalumab + Oleclumab
MedImmune
Stage III Non-small Cell Lung Cancer
1 trial -
MEDI8897
MedImmune
Respiratory Syncytial Virus Infections
1 trial -
MEDI8968 600 mg IV, 300 mg SC
MedImmune
Chronic Obstructive Pulmonary Disease
1 trial -
MEDI9929
MedImmune
Atopic Dermatitis
1 trial -
Monalizumab
MedImmune
Advanced Solid Tumors
1 trial -
Motavizumab, palivizumab
MedImmune
Respiratory Syncytial Virus Infections
1 trial -
Placebo
MedImmune
Asthma
1 trial -
Tralokinumab 300 mg, Q2W
MedImmune
Asthma
1 trial
Frequently asked questions
How many clinical projects does MedImmune have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.